TNB-486
id:
tnb-486-233-6259688
title:
TNB-486
text:
TNB-486 "is a novel CD19xCD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release syndrome by binding to T-cells with low affinity". The drug is developed for cancer by AstraZeneca since its acquisition of TeneoTwo in 2022.
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/TNB-486
date created:
date modified:
2024-02-26T15:07:36Z
main entity:
{"identifier":"Q123575753","url":"https://www.wikidata.org/entity/Q123575753"}
image:
fields total:
13
integrity:
13